Protara Therapeutics (TARA) Q3 2026 earnings summary

Executive summary

• Pipeline programs include TARA-002 for NMIBC and lymphatic malformations (LMs), and IV Choline Chloride for patients receiving parenteral support; no product sales revenue has been generated.

• Q3 2026 net loss was $21.7M versus $13.3M a year earlier; cash, cash equivalents and marketable debt securities totaled $143.1M at September 30.

• November 4 acquisition of TARA-002 manufacturing assets from Novex for $8.75M is intended to bring manufacturing in-house and secure capacity ahead of a potential launch.

• ADVANCED-2 enrollment is targeted to finish by year-end 2026, STARBORN-1 enrollment early Q1 2027, and THRIVE-3 interim results in Q4 2026.

Financial highlights

• Q3 operating expenses and operating loss were each $23.2M versus $14.8M a year earlier; net loss was $21.7M versus $13.3M.

• Q3 R&D expense was $16.8M versus $9.6M YoY; G&A was $6.3M versus $5.2M.

• 9M operating expenses were $66.1M versus $45.5M; net loss was $61.1M versus $40.1M.

• 9M R&D expense rose to $47.3M from $29.5M; G&A increased to $18.8M from $16.0M.

• 9M other income, net, was $5.0M versus $5.3M; prior-year results included $0.5M of nonrecurring refundable tax credits, partly offset by higher 2026 investment income.

Outlook and guidance

• ADVANCED-2 BCG-Unresponsive cohort enrollment is expected to finish in Q4 2026; enrollment is complete in the 31-patient BCG-Naïve cohort.

• THRIVE-3 interim dose-confirmation results are anticipated in Q4 2026; its 24-patient open-label phase completed enrollment in October.

• STARBORN-1 enrollment is targeted for early Q1 2027; a rolling BLA for TARA-002 in LMs is planned to begin in H2 2027.

• Cash resources are expected to fund planned operations and milestones into 2028; additional capital will be needed to fully execute plans.